These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20845812)

  • 1. Prolonged response to cytoreductive surgery and sunitinib in an elderly patient with synchronous multiple metastases from renal cell carcinoma.
    Locatelli MC; Miedico A; D'Antona A; Longo G; Maggioni M; Maggioni A; Tombolini P; Tabiadon D
    Tumori; 2010; 96(3):478-82. PubMed ID: 20845812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery.
    Gorin MA; Ekwenna O; Soloway MS; Ciancio G
    Urology; 2012 Feb; 79(2):e11. PubMed ID: 21676439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.
    Bex A; van der Veldt AA; Blank C; van den Eertwegh AJ; Boven E; Horenblas S; Haanen J
    World J Urol; 2009 Aug; 27(4):533-9. PubMed ID: 19145434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.
    Shaw GL; Hussain M; Nair R; Bycroft J; Beltran L; Green JS; Powles T; Peters JL
    Urol Int; 2012; 89(1):83-8. PubMed ID: 22614181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy.
    Dall'Oglio MF; Sousa-Canavez JM; Tanno FY; Tiseo BC; Crippa A; Dos Reis ST; Leite KR; Srougi M
    Int Braz J Urol; 2011; 37(2):180-5; discussion 185-6. PubMed ID: 21557834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report.
    Messina C; Di Meglio A; Nuzzo PV; Boccardo F; Ricci F
    Tumori; 2015; 101(3):e79-81. PubMed ID: 26417621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
    Yoshinaga A; Kamata S
    Hinyokika Kiyo; 2015 May; 61(5):201-5. PubMed ID: 26087822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
    Méjean A; Ravaud A; Thezenas S; Colas S; Beauval JB; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Beisland C; Aitchison M; Oudard S; Patard JJ; Theodore C; Chevreau C; Laguerre B; Hubert J; Gross-Goupil M; Bernhard JC; Albiges L; Timsit MO; Lebret T; Escudier B
    N Engl J Med; 2018 Aug; 379(5):417-427. PubMed ID: 29860937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
    Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic collecting duct carcinoma of the kidney treated with sunitinib.
    Tazi EM; Essadi I; Tazi MF; Ahellal Y; M'rabti H; Errihani H
    World J Surg Oncol; 2011 Jul; 9():73. PubMed ID: 21752265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neoadjuvant therapy for renal cancer].
    Thibault F; Rixe O; Meric JB; Renard-Penna R; Boostan H; Mozer P; Comperat E; Richard F; Bitker MO
    Prog Urol; 2008 Apr; 18(4):256-8. PubMed ID: 18501308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.
    Seidel C; Fenner M; Merseburger AS; Reuter C; Ivanyi P; Länger F; Ganser A; Grünwald V
    World J Urol; 2011 Jun; 29(3):355-60. PubMed ID: 21258806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a case.
    Ueda K; Noguchi M; Suekane S; Moriya F; Nagayoshi R; Ejima K; Momozono K; Matsuoka K
    Kurume Med J; 2011; 58(3):95-8. PubMed ID: 22531125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Therapy for Renal Cell Carcinoma.
    Joshi R; Rawal S
    JNMA J Nepal Med Assoc; 2015; 53(198):83-8. PubMed ID: 26994026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
    Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
    Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PATHOLOGICAL COMPLETE RESPONSE WITH EVEROLIMUS FOR MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA RESISTANT TO SUNITINIB].
    Namura K; Otake S; Sawada T; Fujikawa A; Ota J; Moriyama M
    Nihon Hinyokika Gakkai Zasshi; 2015 Jan; 106(1):30-4. PubMed ID: 26399128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
    Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
    Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
    Biswas S; Kelly J; Eisen T
    Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.